Chengdu Easton Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Chengdu Easton Biopharmaceuticals has a total shareholder equity of CN¥2.6B and total debt of CN¥200.7M, which brings its debt-to-equity ratio to 7.6%. Its total assets and total liabilities are CN¥3.4B and CN¥748.3M respectively. Chengdu Easton Biopharmaceuticals's EBIT is CN¥169.0M making its interest coverage ratio -8.4. It has cash and short-term investments of CN¥1.5B.
Key information
7.6%
Debt to equity ratio
CN¥200.72m
Debt
Interest coverage ratio | -8.4x |
Cash | CN¥1.49b |
Equity | CN¥2.63b |
Total liabilities | CN¥748.26m |
Total assets | CN¥3.37b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 688513's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥666.7M).
Long Term Liabilities: 688513's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥81.6M).
Debt to Equity History and Analysis
Debt Level: 688513 has more cash than its total debt.
Reducing Debt: 688513's debt to equity ratio has increased from 0.2% to 7.6% over the past 5 years.
Debt Coverage: 688513's debt is well covered by operating cash flow (156.5%).
Interest Coverage: 688513 earns more interest than it pays, so coverage of interest payments is not a concern.